Biomarkers for chronic fatigue

Nancy G. Klimas, Gordon Broderick, Mary Ann Fletcher

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Fatigue that persists for 6. months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Inflammation, immune system activation, autonomic dysfunction, impaired functioning in the hypothalamic-pituitary-adrenal axis, and neuroendocrine dysregulation have all been suggested as root causes of fatigue. The identification of objective markers consistently associated with CFS/ME is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. This review is focused on the recent literature related to biomarkers for fatigue associated with CFS/ME and, for comparison, those associated with other diseases. These markers are distributed across several of the body's core regulatory systems. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine and immune systems. We propose that new insight will depend on our ability to develop and deploy an integrative profiling of CFS/ME pathogenesis at the molecular level. Until such a molecular signature is obtained efforts to develop effective treatments will continue to be severely limited.

Original languageEnglish
Pages (from-to)1202-1210
Number of pages9
JournalBrain, Behavior, and Immunity
Volume26
Issue number8
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Chronic Fatigue Syndrome
Fatigue
Biomarkers
Immune System
Endocrine System
Nervous System
Signs and Symptoms
Inflammation

ASJC Scopus subject areas

  • Immunology
  • Behavioral Neuroscience
  • Endocrine and Autonomic Systems

Cite this

Klimas, N. G., Broderick, G., & Fletcher, M. A. (2012). Biomarkers for chronic fatigue. Brain, Behavior, and Immunity, 26(8), 1202-1210. https://doi.org/10.1016/j.bbi.2012.06.006

Biomarkers for chronic fatigue. / Klimas, Nancy G.; Broderick, Gordon; Fletcher, Mary Ann.

In: Brain, Behavior, and Immunity, Vol. 26, No. 8, 01.11.2012, p. 1202-1210.

Research output: Contribution to journalArticle

Klimas, NG, Broderick, G & Fletcher, MA 2012, 'Biomarkers for chronic fatigue', Brain, Behavior, and Immunity, vol. 26, no. 8, pp. 1202-1210. https://doi.org/10.1016/j.bbi.2012.06.006
Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain, Behavior, and Immunity. 2012 Nov 1;26(8):1202-1210. https://doi.org/10.1016/j.bbi.2012.06.006
Klimas, Nancy G. ; Broderick, Gordon ; Fletcher, Mary Ann. / Biomarkers for chronic fatigue. In: Brain, Behavior, and Immunity. 2012 ; Vol. 26, No. 8. pp. 1202-1210.
@article{985399947867429e861e4dce7fddc84d,
title = "Biomarkers for chronic fatigue",
abstract = "Fatigue that persists for 6. months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Inflammation, immune system activation, autonomic dysfunction, impaired functioning in the hypothalamic-pituitary-adrenal axis, and neuroendocrine dysregulation have all been suggested as root causes of fatigue. The identification of objective markers consistently associated with CFS/ME is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. This review is focused on the recent literature related to biomarkers for fatigue associated with CFS/ME and, for comparison, those associated with other diseases. These markers are distributed across several of the body's core regulatory systems. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine and immune systems. We propose that new insight will depend on our ability to develop and deploy an integrative profiling of CFS/ME pathogenesis at the molecular level. Until such a molecular signature is obtained efforts to develop effective treatments will continue to be severely limited.",
author = "Klimas, {Nancy G.} and Gordon Broderick and Fletcher, {Mary Ann}",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.bbi.2012.06.006",
language = "English",
volume = "26",
pages = "1202--1210",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",
number = "8",

}

TY - JOUR

T1 - Biomarkers for chronic fatigue

AU - Klimas, Nancy G.

AU - Broderick, Gordon

AU - Fletcher, Mary Ann

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Fatigue that persists for 6. months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Inflammation, immune system activation, autonomic dysfunction, impaired functioning in the hypothalamic-pituitary-adrenal axis, and neuroendocrine dysregulation have all been suggested as root causes of fatigue. The identification of objective markers consistently associated with CFS/ME is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. This review is focused on the recent literature related to biomarkers for fatigue associated with CFS/ME and, for comparison, those associated with other diseases. These markers are distributed across several of the body's core regulatory systems. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine and immune systems. We propose that new insight will depend on our ability to develop and deploy an integrative profiling of CFS/ME pathogenesis at the molecular level. Until such a molecular signature is obtained efforts to develop effective treatments will continue to be severely limited.

AB - Fatigue that persists for 6. months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Inflammation, immune system activation, autonomic dysfunction, impaired functioning in the hypothalamic-pituitary-adrenal axis, and neuroendocrine dysregulation have all been suggested as root causes of fatigue. The identification of objective markers consistently associated with CFS/ME is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. This review is focused on the recent literature related to biomarkers for fatigue associated with CFS/ME and, for comparison, those associated with other diseases. These markers are distributed across several of the body's core regulatory systems. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine and immune systems. We propose that new insight will depend on our ability to develop and deploy an integrative profiling of CFS/ME pathogenesis at the molecular level. Until such a molecular signature is obtained efforts to develop effective treatments will continue to be severely limited.

UR - http://www.scopus.com/inward/record.url?scp=84867225089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867225089&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2012.06.006

DO - 10.1016/j.bbi.2012.06.006

M3 - Article

VL - 26

SP - 1202

EP - 1210

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

IS - 8

ER -